Connecting New Innovation to Improve Sepsis Care: The Development Story
In the U.S., more than 1.7 million people are diagnosed with sepsis and 270,000 people die from sepsis each year. Sepsis is the #1 cost of hospitalization in the U.S. with estimated costs for acute sepsis hospitalization and skilled nursing at $62 billion annually. New innovative technologies can help to improve sepsis care and decrease cost. Learn from four companies about their journeys from visions to improve sepsis care to development of novel technologies to clinical validation. Medical device, diagnostic, and health innovation companies in the pre-commercial and established implementation phases of product development will share their experiences including challenges, observations, and solutions. The innovation and development process in relationship to the needs of patients and healthcare providers will be considered with the goal to improve sepsis care.
This course was originally recorded in September 2020 as part of the 2020 Sepsis Alliance Summit.
Nurses, physicians, pharmacists, emergency responders, healthcare management teams, and other healthcare staff may benefit.
At the end of the presentation, the learner should be able to:
- Review the development path for some innovative technologies.
- Discuss challenges to and opportunities for transitioning new innovative ideas to product development, to regulatory approval, and into clinical practice.
- Identify barriers to adoption and implementation of new technologies.
- Describe how collaboration, communication, and knowledge sharing between innovators and healthcare providers can improve product development.
Moderator: Kimberly Sciarretta, PhD
HHS/ASPR/BARDA DRIVe Solving Sepsis Program Manager
Kimberly Sciarretta, PhD is the Solving Sepsis Program Manager within the Division of Research Innovation and Ventures (DRIVe), Biomedical Advanced Research and Development Authority (BARDA), part of the Assistant Secretary for Preparedness and Response (ASPR), within the United States Department of Health and Human Services (HHS). Previously Dr. Sciarretta was a Project Officer within the BARDA CBRN Division, and prior to that, was a technical consultant to multiple US Government Agencies. Dr. Sciarretta was one of the inaugural members of DRIVe and is leading efforts towards improving patient outcomes for sepsis through strategic interagency activities and critical technology investments with external partners. Dr. Sciarretta received her PhD from the University of Chicago in Molecular Genetics and Cell Biology. Her expertise broadly spans medical countermeasure development, biochemistry, synthetic biology, advanced manufacturing and chemical and biological defense technologies.
Klaudyne Hong, PhD
Chief Executive Officer, Peach IntelliHealth
Klaudyne Hong, PhD, is CEO of Peach IntelliHealth, an AI healthcare company. She became intrigued with AI predictive analytics while watching the movie “Minority Report”. A decade later, while fly fishing, she had an epiphany about creating a new type of Machine Learning technology that could be used by healthcare professionals to predict adverse medical events in patients and prevent them. Peach was formed soon after. Prior to Peach, Dr Hong was a pharma executive at Johnson & Johnson and Schering AG, leading teams in stem cells, gene therapy, vaccine, and oncology. Her technology, publication, and patent portfolio includes research and development in Alzheimer’s, cancer, cardiovascular disease, infectious disease, multiple sclerosis, Parkinson’s, stroke, and spinal cord injury. Dr Hong received her PhD from the Massachusetts Institute of Technology and her MA and BA from California State University Fresno. She works in New York and Singapore.
Rajesh Krishnamurthy, PhD
Chief Technology Officer, 3iDx
Dr. Krishnamurthy has over 20 years of experience in developing therapeutic products and diagnostics. He has overseen the development of over 50 products at different stages of development including two billion dollar drugs - Kadcyla® (breast cancer) and Tanzeum® (diabetes). Prior to starting 3i, he was the Director of Pharmaceutical Development at Zyngenia, Senior Director of Analytical & Pharmaceutical Sciences at ImmunoGen, and Associate Director of Pharmaceutical Sciences at Human Genome Sciences (a subsidiary of GSK).
Chief Executive Officer & Co-founder, Patch'd Medical
Robert is the CEO and Co-founder of Patchd Medical. Robert started his career studying both Biomedical Science majoring in Neuroscience and Mechatronic Engineering. During his time studying, he worked in a number of labs conducting research on the cerebellum to working with silicon retinas which sparked his intense interest in the intersection of engineering and science. After graduating Robert then briefly worked in corporate strategy before realizing his true passion was to become an entrepreneur to help solve Sepsis, a condition which had nearly taken his life. With his co-founder Wei-Jien, they started Patchd and within 12 months they were part of the prestigious Y Combinator accelerator. Together they work to use deep learning and off the shelf wearables to help predict the onset of this devastating condition.
President and CEO, Daxor Corporation
Michael Feldschuh has held the position of president and CEO of Daxor Corporation since December 2015. Prior to this, he served as a member of the Board of Directors before joining Daxor’s executive team in December of 2014. Michael has over 25 years of experience in the medical field and on Wall Street. He served as a managing director and portfolio manager for Morgan Stanley for six years and a managing director of Millennium Partners for eight years in addition to leading his own hedge fund, Aristarc Capital, from 2009 to 2013. Michael began his career at D.E. Shaw & Co. in New York, where he worked with Jeffery Bezos prior to Bezos’s founding of Amazon. Michael earned his bachelor’s degree in pre-medical studies at Columbia College, Columbia University in 1991. Michael’s interests include photography and travel.
No continuing education credits are offered for this session.
The information on or available through this site is intended for educational purposes only. Sepsis Alliance does not represent or guarantee that information on or available through this site is applicable to any specific patient’s care or treatment. The educational content on or available through this site does not constitute medical advice from a physician and is not to be used as a substitute for treatment or advice from a practicing physician or other healthcare provider. Sepsis Alliance recommends users consult their physician or healthcare provider regarding any questions about whether the information on or available through this site might apply to their individual treatment or care.
- 1.00 Participation